News
Anaerobically prepared donor FMT led to steroid-free remission of ulcerative colitis
Eight weeks after FMT, 32% of the donor group achieved steroid-free remission, compared with 9% of the autologous FMT group (odds ratio, 5; P...
News
INPULSIS-ON: Nintedanib shows manageable long-term safety for IPF
IFP has had a poor prognosis and long-term data on treatment options are needed.
News
Platinum-etoposide, taxanes best for small cell transformed EGFR-mutant lung cancer
Both platinum-etoposide and taxane therapies produced high response rates (71% each), but patients did not respond to checkpoint inhibitor therapy...
News
Adding veliparib to doublet therapy for NSCLC gives slight boost in PFS
Median progression-free survival was 6.1 months for veliparib plus cisplatin-etoposide versus 5.5 months for placebo plus cisplatin-etoposide.
News
Low-normal thyroid function tied to advanced fibrosis
In all, 5.9% of adults with low-normal thyroid function had advanced liver fibrosis, compared with 2.8% of individuals with strict-normal thyroid...
News
Adverse events a potential concern for chemotherapy-nivolumab in advanced gastric cancer
Adverse events led to dose delays or reductions in 95% of patients. Serious adverse events affected 15% of patients and in most cases led them to...
News
Plerixafor produced dramatic responses in severe WHIM syndrome
The treatment was effective and well tolerated in patients who could not receive granulocyte colony-stimulating factor therapy.
News
CRP predicts anti-TNF response in ankylosing spondylitis
A baseline C-reactive protein level more than three times above the upper limit of normal correlated significantly with 12-week etanercept...
News
Nuedexta mainly prescribed for dementia, Parkinson’s
Only 15.2% of patients had multiple sclerosis or amyotrophic lateral sclerosis, the diagnoses of patients in the studies leading to the approval...
News
Pyrotinib shows promise in HER2-mutant non–small cell lung cancer
In a phase 2 trial of 15 adults with progressive HER2-mutant NSCLC, objective response rate was 53%, median overall survival was 12.9 months, and...
News
Childhood inflammatory bowel disease linked to increased mortality
The risk of death was three- to fivefold higher than that in the general population.
News
Metachronous advanced neoplasia linked to diminutive polyp number, not histology
Metachronous advanced neoplasia was diagnosed in similar proportions of patients with and without high-risk diminutive polyps.
News
Studies support vedolizumab-calcineurin inhibitor combinations but not accelerated infliximab therapy for refractory UC
Rates of colectomy were similar whether patients received induction immunotherapy with infliximab at weeks 0, 2, and 6, or on an accelerated...
News
Study supports swallowed topical steroids as maintenance for eosinophilic esophagitis
Rates of clinical remission were 16.1% and 1.3%, respectively (P less than .001).
News
Vedolizumab, tofacitinib induced rapid improvements in IBD symptoms
Two recent studies highlight the ability of vedolizumab and tofacitinib to rapidly improve symptoms reported by patients with inflammatory bowel...